A New Chapter in Precision Medicine for Neurodegenerative Diseases Opened by Exosomes
Microscopic Messengers Threatening the Brain, Exosomes
Exosomes are nanoscale extracellular vesicles (EVs) that carry proteins, lipids, mRNA, and non‑coding RNA, reflecting the state of their parent cells. Because they can cross the blood‑brain barrier (BBB), they have attracted attention as biomarkers and delivery vectors in neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and multiple sclerosis. However, a major challenge is that these tiny particles can also disseminate pathological proteins.
Innovative Isolation and Analysis Technologies Opening New Paths
Microfluidic‑based isolation and single‑vesicle analysis have revolutionized exosome research. Multi‑omics profiling has precisely captured disease‑specific proteins such as amyloid‑β (Aβ), tau, and α‑synuclein, as well as regulatory microRNA (miRNA) signatures. This high‑resolution data surpasses previous detection limits and markedly enhances the potential for early diagnosis.
Therapeutic Candidates and Tailored Delivery Systems
Stem cell‑derived exosomes are emerging as naturally compatible therapeutic candidates. Surface‑engineered vesicles loaded with neuroprotective miRNAs are reported to reach damaged neural circuits directly, suppress inflammation, and promote regeneration. This approach can overcome the BBB penetration issues of conventional drugs while minimizing side effects.
The Future of Precision Medicine: Exosomes
It is anticipated that exosome‑based biomarkers and therapeutics will be integrated, making personalized management of neurological disorders a reality. As the technology matures, a single drop of blood could monitor disease progression and enable immediate, customized exosome therapy, substantially improving quality of life.
Exosomes are nanoscale extracellular vesicles (EVs) that mediate intercellular communication and carry proteins, lipids, mRNAs, and non-coding RNAs reflective of their parental cells. Their biogenesis, molecular composition, and ability to traverse physiological barriers, including the blood-brain barrier, position exosomes as powerful candidates for biomarker development and therapeutic delivery in neurodegenerative diseases (NDDs). In Alzheimer's disease, Parkinson's disease, multiple sclerosis, and prion disorders, exosomes not only mirror pathological processes but actively participate in the propagation of misfolded proteins and neuroinflammatory signals through cell-type-specific vesicle subpopulations. This review synthesises current advances in exosome biology, cargo sorting, release mechanisms, and pathophysiological roles in the central nervous system, with emphasis on how neuron-, astrocyte-, and microglia-derived exosomes diverge in their cargo profiles and functional consequences across diseases. We highlight disease-specific exosomal signatures, including amyloid-β (Aβ), tau, α-synuclein, myelin proteins, prion proteins (PrP) and regulatory microRNAs. We evaluate emerging technologies such as microfluidic isolation, single-vesicle analysis, and multi-omics profiling that are accelerating biomarker discovery, and review exosome-based therapeutic strategies, including native stem cell-derived exosomes and surface-engineered vesicles loaded with neuroprotective miRNAs, small molecules, and gene-editing cargo. We address critical unmet challenges in translating these approaches to the clinic, including scalable and standardised production, incomplete pharmacokinetic /pharmacodynamic characterisation in preclinical models, immunogenicity and off-target safety concerns, and the absence of specific regulatory guidance for EV drug products. Together, these insights highlight the transformative potential of exosomes as both precision diagnostic tools and diseas
Neurodegenerative diseases are often difficult to diagnose early, leading to missed therapeutic windows. Exosome‑based testing enables rapid and accurate diagnosis, allowing for early management and personalized treatment in everyday life.